TY - JOUR
T1 - Serum profiles of monocyte chemoattractant protein-1 as a biomarker for patients recovering from myocardial infarction
AU - Korybalska, Katarzyna
AU - Pyda, Małgorzata
AU - Grajek, Stefan
AU - Łanocha, Magdalena
AU - Brȩborowicz, Andrzej
AU - Witowski, Janusz
PY - 2010/5
Y1 - 2010/5
N2 - Background: Monocyte chemoattractant protein-1 (MCP-1) plays a key role in the pathogenesis of atherosclerosis and has been proposed as a biomarker for patients with cardiovascular disease. Methods: To assess its clinical usefulness, serum MCP-1 concentrations were measured in patients with ST-elevation myocardial infarction (MI) at admission, immediately after percutaneous coronary intervention (PCI), at 24 h, and after 6 months. Results: We found no differences in MCP-1 concentrations between patients with acute MI, patients with stable coronary artery disease and healthy individuals. Although median MCP-1 concentrations in patients with MI were similar at admission and after 6 months, there were significant differences between individuals in how MCP-1 levels changed with time. As demonstrated by comparing baseline quartiles of MCP-1, the levels of MCP-1 tended to increase in patients with low MCP-1 concentration at admission, and decrease in patients with initially high MCP-1 levels. We found an inverse correlation between MCP-1 concentration at baseline and the time to reperfusion, and detected a significant decrease in MCP-1 concentration immediately after PCI. We also observed lower MCP-1 concentrations over time in patients who developed restenosis within 6 months. However, we did not confirm the association between MCP-1 concentrations at baseline and a number of previously implicated demographic, clinical and laboratory criteria. Conclusions: Our data demonstrate some new aspects of MCP-1 measurement in patients with MI, but do not corroborate many earlier observations.
AB - Background: Monocyte chemoattractant protein-1 (MCP-1) plays a key role in the pathogenesis of atherosclerosis and has been proposed as a biomarker for patients with cardiovascular disease. Methods: To assess its clinical usefulness, serum MCP-1 concentrations were measured in patients with ST-elevation myocardial infarction (MI) at admission, immediately after percutaneous coronary intervention (PCI), at 24 h, and after 6 months. Results: We found no differences in MCP-1 concentrations between patients with acute MI, patients with stable coronary artery disease and healthy individuals. Although median MCP-1 concentrations in patients with MI were similar at admission and after 6 months, there were significant differences between individuals in how MCP-1 levels changed with time. As demonstrated by comparing baseline quartiles of MCP-1, the levels of MCP-1 tended to increase in patients with low MCP-1 concentration at admission, and decrease in patients with initially high MCP-1 levels. We found an inverse correlation between MCP-1 concentration at baseline and the time to reperfusion, and detected a significant decrease in MCP-1 concentration immediately after PCI. We also observed lower MCP-1 concentrations over time in patients who developed restenosis within 6 months. However, we did not confirm the association between MCP-1 concentrations at baseline and a number of previously implicated demographic, clinical and laboratory criteria. Conclusions: Our data demonstrate some new aspects of MCP-1 measurement in patients with MI, but do not corroborate many earlier observations.
KW - Acute coronary syndrome
KW - Left ventricular function
KW - Monocyte chemoattractant protein-1
KW - Restenosis
UR - http://www.scopus.com/inward/record.url?scp=77954658890&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77954658890&partnerID=8YFLogxK
U2 - 10.1007/s00392-010-0122-1
DO - 10.1007/s00392-010-0122-1
M3 - Article
C2 - 20140679
AN - SCOPUS:77954658890
SN - 1861-0684
VL - 99
SP - 315
EP - 322
JO - Clinical Research in Cardiology
JF - Clinical Research in Cardiology
IS - 5
ER -
